Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OriolaCHIX:ORIOLH 38 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates CHIX:ORIOLH with a GF Score™ of 38/100 and a GF Value™ of €1.01. The stock has 5 warning signs investors should review. Among 528 Healthcare Providers & Services companies, Oriola ranks worse than 189393.75% on this metric.
During the past 12 months, Oriola's average EBITDA Per Share Growth Rate was -26.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Oriola was 52.10% per year. The lowest was -27.40% per year. And the median was -10.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
For the Pharmaceutical Retailers subindustry, Oriola's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oriola 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Oriola's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Oriola's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Oriola (CHIX:ORIOLH) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Oriola and its competitors. According to the industry distribution chart, Oriola ranks #999999 out of 528 companies in the Healthcare Providers & Services industry.
Is Oriola's 3-Year EBITDA Growth Rate too high?
Oriola's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Oriola ranks #999999 out of 528 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Oriola has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Oriola's 3-Year EBITDA Growth Rate compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Oriola ranks #999999 out of 528 companies for 3-Year EBITDA Growth Rate. This places Oriola in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 528 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Oriola and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oriola's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oriola stock overvalued right now?
Oriola (CHIX:ORIOLH) has a current 3-Year EBITDA Growth Rate of 0.00%. The stock's GF Value™ is €1.01, compared to a current price of €0.94 — trading 7.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Oriola's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Oriola (CHIX:ORIOLH), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oriola (CHIX:ORIOLH) Overvalued in 2026?
Based on GuruFocus' analysis, Oriola stock appears to be undervalued.
The current stock price of €0.94 is trading 7.1% below its estimated GF Value™ of €1.01.
Key valuation signals for CHIX:ORIOLH:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: €1.01 vs. price of €0.94 (7.1% below fair value)
No single metric tells the full story. See the CHIX:ORIOLH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oriola Corp is a health and wellbeing company operating in Nordic countries. It offers services such as the distribution of pharmaceuticals and other health and well-being products, services, and dose dispensing. Oriola's operations are divided into two segments which include distribution and wholesale. Geographically, the company operates in Sweden, Finland and other countries generating majority revenue from the region of Sweden.
38GF Score
Get the complete analysis for CHIX:ORIOLH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ORIOLH has been successfully added to your 
